This prespecified analysis of the SELECT trial examined the long-term effects of semaglutide on weight and anthropometric outcomes in adults with established cardiovascular disease, overweight or obesity, and without diabetes. Semaglutide resulted in sustained weight loss (-10.2%) and improvements in waist circumference and waist-to-height ratio compared to placebo. Clinically meaningful weight loss was observed across various demographics. While semaglutide was associated with fewer serious adverse events, it also led to increased rates of trial product discontinuation, particularly in lower BMI categories. The study confirms the efficacy and safety of semaglutide for long-term weight management in this population.

Donna H. Ryan, Ildiko Lingvay, John Deanfield, Steven E. Kahn, Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato, Dror Dicker, Deborah B. Horn, G. Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A. Michael Lincoff, Sebastian M. Meyhöfer, Tugce Kalayci Oral, Jorge Plutzky, André P. van Beek, John P. H. Wilding, Robert F. Kushner